General Information of Drug (ID: DMRZY0B)

Drug Name
4-(2,2'-bithiophen-5-ylmethyleneamino)phenol Drug Info
Synonyms
MLS000106248; SMR000103217; CHEMBL504791; 4-[(5-thiophen-2-ylthiophen-2-yl)methylideneamino]phenol; AC1LGKRK; cid_796420; BDBM29642; HMS2448D05; MCULE-1982148585; SR-01000609337; SR-01000609337-2; 4-[[5-(2-thienyl)-2-thienyl]methyleneamino]phenol
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
796420
TTD Drug ID
DMRZY0B

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Matrix metalloproteinase-13 (MMP-13) TTHY57M MMP13_HUMAN Inhibitor [1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Matrix metalloproteinase-13 (MMP-13) DTT MMP13 1.263 4.603 2.138 1.963
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Discovery agent
ICD Disease Classification N.A.
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Matrix metalloproteinase-13 (MMP-13) DTT MMP13 1.25E-03 0.76 1.3
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg Med Chem. 2009 Feb 1;17(3):990-1005.